IQAC, CSIC, Jordi Girona 18-26, E-08034-Barcelona, Spain.
Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology (BIST), E-08028-Barcelona, Spain.
Nanoscale. 2023 May 4;15(17):7929-7944. doi: 10.1039/d2nr07256d.
A hydroxycinnamic acid derivative, namely ferulic acid (FA) has been successfully encapsulated in polymeric nanoparticles (NPs) based on poly(lactic--glycolic acid) (PLGA). FA-loaded polymeric NPs were prepared from O/W nano-emulsion templates using the phase inversion composition (PIC) low-energy emulsification method. The obtained PLGA NPs exhibited high colloidal stability, good drug-loading capacity, and particle hydrodynamic diameters in the range of 74 to 117 nm, depending on the FA concentration used. drug release studies confirmed a diffusion-controlled mechanism through which the amount of released FA reached at 60% after 6 hours-incubation. Five kinetic models were used to fit the FA release data as a function of time. The Weibull distribution and Korsmeyer-Peppas equation models provided the best fit to our experimental data and suggested quasi-Fickian diffusion behaviour. Moderate dose-response antioxidant and radical scavenging activities of FA-loaded PLGA NPs were demonstrated using the DPPH˙ assay achieving inhibition activities close to 60 and 40%, respectively. Cell culture studies confirmed that FA-loaded NPs were not toxic according to the MTT colorimetric assay, were able to internalise efficiently SH-SY5Y neuronal cells and supressed the intracellular ROS-level induced by HO leading to 52% and 24.7% of cellular viability at 0.082 and 0.041 mg mL, respectively. The permeability of the NPs through the blood brain barrier was tested with an organ-on-a-chip model to evaluate the ability of the FA-loaded PLGA and non-loaded PLGA NPs to penetrate to the brain. NPs were able to penetrate the barrier, but permeability decreased when FA was loaded. These results are promising for the use of loaded PLGA NPs for the management of neurological diseases.
一种羟基肉桂酸衍生物,即阿魏酸(FA),已成功封装在基于聚(乳酸-乙醇酸)(PLGA)的聚合物纳米颗粒(NPs)中。使用相转变组成(PIC)低能量乳化法,从 O/W 纳米乳液模板制备 FA 负载的聚合物 NPs。所得的 PLGA NPs 表现出高胶体稳定性、良好的载药能力和粒径在 74 至 117nm 范围内,这取决于所用 FA 的浓度。药物释放研究证实了扩散控制机制,其中在 6 小时孵育后,释放的 FA 量达到 60%。使用了五个动力学模型来拟合 FA 释放数据随时间的变化。Weibull 分布和 Korsmeyer-Peppas 方程模型为我们的实验数据提供了最佳拟合,表明准 Fickian 扩散行为。使用 DPPH˙ 测定法,对负载 FA 的 PLGA NPs 的适度剂量反应抗氧化和自由基清除活性进行了证明,达到了接近 60%和 40%的抑制活性。细胞培养研究证实,根据 MTT 比色法,负载 FA 的 NPs 没有毒性,能够有效地内化 SH-SY5Y 神经元细胞,并抑制由 HO 诱导的细胞内 ROS 水平,在 0.082 和 0.041mg/mL 时,细胞活力分别达到 52%和 24.7%。通过器官芯片模型测试 NPs 通过血脑屏障的通透性,以评估负载 FA 的 PLGA 和非负载 PLGA NPs 穿透大脑的能力。NPs 能够穿透屏障,但当 FA 负载时,渗透性降低。这些结果为使用负载 PLGA NPs 管理神经疾病提供了希望。